Secretome of Hypoxia-Preconditioned Mesenchymal Stem Cells Promotes Liver Regeneration and Anti-Fibrotic Effect in Liver Fibrosis Animal Model
Bukhari A., Hardjo M., Patellongi I., Achmad M.H., Putra A., Daud N.A.S., Amansyah F., Parewangi L., Budu B., Massi M.N.
Abstract
Background and Objective: Liver fibrosis (LF) is a most common pathological process characterized by the activation of hepatocytes leading to the accumulation of extracellular matrix (ECM). Hypoxia precondition treated in MSCs (H-MSCs) could enhance their immunomodulatory and regeneration capability, through expressing robust anti-inflammatory cytokines and growth factors, known as H-MSCs secretome (SH-MSCs) that are critical for the improvement of liver fibrosis. However, the study regarding the efficacy and mechanism of action of SH-MSCs in ameliorating liver fibrosis is still inconclusive. In this study, the therapeutic potential and underlying mechanism for SH-MSCs in the treatment of liver fibrosis were investigated. Materials and Methods: A rat model with liver fibrosis induced by CCl<inf>4</inf> was created and maintained for 8 weeks. The rats received intravenous doses of SH-MSCs and secretome derived from normoxia MSCs (SN-MSCs), filtered using a tangential flow filtration (TFF) system with different molecular weight cut-off categories, both at a dosage of 0.5 mL. The ELISA assay was employed to examine the cytokines and growth factors present in both SH-MSCs and SN-MSCs. On the ninth day, the rats were euthanized and liver tissues were collected for subsequent histological examination and analysis of mRNA expression. Results: The ELISA test revealed that SH-MSCs exhibited higher levels of VEGF, PDGF, bFGF, IL-10, TGF-β and IL-6 compared to SN-MSCs. In vivo, administration of SH-MSCs notably decreased mortality rates. It also demonstrated a reduction in liver fibrosis, collagen fiber areas, α-SMA positive staining and relative mRNA expression of TGF-β. Conversely, SN-MSCs also contributed to liver fibrosis improvement, although SH-MSCs demonstrated more favorable outcomes. Conclusion: Current findings suggested that SH-MSCs could improve CCl<inf>4</inf>-induced liver fibrosis and decrease α-SMA and TGF-β expression.
The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis
Dai L.-J., Dai L.-J., Guan L.-X., Li H.Y., Ritchie G., Zhou J.X., Dai L.-J., Dai L.-J., Guan L.-X., Li H.Y., Ritchie G., Zhou J.X.
Targeting TGF-β signaling for the treatment of fibrosis
Distler J.H.W., Gyorfi A.H., Matei A.-E., Distler J.H.W., Gyorfi A.H., Matei A.-E.
U-Shape Suppressive Effect of Phenol Red on the Epileptiform Burst Activity via Activation of Estrogen Receptors in Primary Hippocampal Culture
Chen B., Chen L., Fan W., Liu J., Liu X., Ren W.-T., Wang G., Wang X., Wang Y.
Cytotoxicity of phenol red in toxicity assays for carbon nanoparticles
Fan C., Huang Q., Li W., Li Y., Zhang X., Zhao Q., Zhu J., Zhu Y.
Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo
Berthiaume F., Cho C.H., Nahmias Y., Parekkadan B., Parekkadan B., Tilles A.W., Van Poll D., Van Poll D., Yarmush M.L., Yarmush M.L., Yarmush M.L.
Angiogenesis and liver fibrosis
Elpek G.O., Elpek G.O.
The discovery of Hepatocyte Growth Factor (HGF) and its significance for cell biology, life sciences and clinical medicine
Mizuno S., Nakamura T.
Hypoxia-preconditioned mesenchymal stem cells ameliorate ischemia/reperfusion-induced lung injury
Chen W.-C., Chen W.-C., Chian C.-F., Chiang C.-H., Chiang C.-H., Chiang C.-H., Hung S.-C., Hung S.-C., Hung S.-C., Hung S.-C., Liu Y.-Y., Liu Y.-Y., Tsai C.-L., Zhang H.
Mesenchymal stem cells and their secreted molecules predominantly ameliorate fulminant hepatic failure and chronic liver fibrosis in mice respectively
Cheng X., Da Y., Ga hu Z., Gao F., Hu Y., Huang B., Huang W., Qiao L., Wang D., Wang H., Wang H., Xue Z., Yao Z., Zhang H., Zhang K., Zhang N., Zhang R.
Effects of bone marrow-derived mesenchymal stem cells on hypoxia and the transforming growth factor beta 1 (TGF-β1) and SMADs pathway in a mouse model of cirrhosis
Chen T., Li J., Xiao P., Xie X., Yan X., Zhang L., Zhang L., Zhou D., Zhu J.
